Advanced Cell Technology Provides Update on Its Myoblast Program.
Business Wire › September 29, 2010
Linked as:
Extract
Advanced Cell Technology Provides Update on Its Myoblast Program.
MARLBOROUGH, Mass. -- Advanced Cell Technology ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clin...
See the full content of this document
Sponsored links
